NIBR chief Jay Bradner joins the exodus at Novartis, handing the keys to Fiona Marshall
Seven years ago, Jay Bradner left high-profile posts at Harvard Med and Dana-Farber and jumped to the leadership role at Novartis’ global research arm, the storied Novartis Institutes for BioMedical Research, where one of his first jobs was reorganizing the group and cutting staff. And today we learned that he’s wrapping up his stint at the pharma giant in the midst of a major shakeup that forced development chief John Tsai out.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.